{
    "clinical_study": {
        "@rank": "129321", 
        "arm_group": {
            "arm_group_label": "LEE011", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "LEE011 is a small molecule inhibitor of CDK4/6.  LEE011 has demonstrated in vitro and in\n      vivo activity in both tumor models.\n\n      The primary purpose of this study is to determine the maximum tolerated dose (MTD) and/or\n      recommended dose for expansion (RDE) in pediatric patients and to delineate a clinical dose\n      to be used in future studies. This study will also assess the safety, tolerability, PK and\n      preliminary evidence of antitumor activity of LEE011 in patients with MRT or neuroblastoma."
        }, 
        "brief_title": "Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Rhabdoid Tumors (MRT), Neuroblastoma", 
        "condition_browse": {
            "mesh_term": [
                "Neuroblastoma", 
                "Rhabdoid Tumor"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of MRT  or, neuroblastoma or in dose escalation part, other\n             tumors with documented evidence of D-cyclin-CDK4/6-INK4a-Rb pathway abnormalities\n             (dose escalation part only),\n\n          -  Patients with CNS disease should be on stable doses of steroids for at least 7 days\n             prior to first dose of LEE011 with no plans for escalation.\n\n          -  In expansion part, patients must have at least one measurable disease as defined by\n             RECIST v1.1.\n\n          -  Patients must have a Lansky (\u2264 16 years) or Karnofsky (> 16 years) score of at least\n             50.\n\n        Exclusion Criteria:\n\n          -  Prior history of QTc prolongation or QTcF > 450 ms on screening ECG.\n\n          -  Patients with the following laboratory values during screening:\n\n               -  Serum creatinine > 1.5 x upper limit of normal (ULN) for age\n\n               -  Total bilirubin >1.5 x ULN for age\n\n               -  Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) > 3 x\n                  ULN for age; aspartate aminotransferase (AST)/serum glutamic oxaloacetic\n                  transaminase(SGOT) > 3 x ULN for age except in patients with tumor involvement\n                  of the liver who must have AST/SGOT and ALT/SGPT \u2264 5 x ULN for age. For the\n                  purpose of this study, the ULN for SGPT/ALT is 45 U/L.\n\n          -  Patients who are currently receiving treatment with agents that are metabolized\n             predominantly through CYP3A4/5 and have a narrow therapeutic window and/or agents\n             that are known strong inducers or inhibitors CYP3A4/5 are prohibited. In particular,\n             enzyme-inducing antiepileptic drugs (EIAEDs).\n\n          -  Other severe acute or chronic medical or psychiatric condition or laboratory\n             abnormality that may interfere with the interpretation of study results, and in the\n             judgment of the investigator would make the patient inappropriate for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747876", 
            "org_study_id": "CLEE011X2102"
        }, 
        "intervention": {
            "arm_group_label": "LEE011", 
            "description": "LEE011 is a small molecule inhibitor of CDK4/6.", 
            "intervention_name": "LEE011", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "pediatric", 
            "CDK4/6 inhibitor", 
            "dose escalation", 
            "malignant rhabdoid tumors", 
            "MRT", 
            "neuroblastoma"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Sharon.Kresge@ucsf.edu", 
                    "last_name": "Sharon Kresge", 
                    "phone": "415-514-3658"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94101"
                    }, 
                    "name": "University of California San Francisco Dept of Pediatic Oncology"
                }, 
                "investigator": {
                    "last_name": "Steven Dubois", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "katherine.garrett@choa.org", 
                    "last_name": "Katherine Garrett", 
                    "phone": "404-785-3535"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "Children's Healthcare of Atlanta Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Muna Qayed", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nathan_pinches@dfci.harvard.edu", 
                    "last_name": "Nathan Pinches", 
                    "phone": "617-632-6308"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute SC-7"
                }, 
                "investigator": {
                    "last_name": "Susan Chi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chambee1@mskcc.org", 
                    "last_name": "Elizabeth Chamberlain", 
                    "phone": "646-888-5716"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Shakeel Modak", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jenny.quinn@cchmc.org", 
                    "last_name": "Jenny T Thomas", 
                    "phone": "513-636-9419"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229-3039"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "James Geller", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "camburnd@email.chop.edu", 
                    "last_name": "Devaney Camburn", 
                    "phone": "267-426-9293"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4399"
                    }, 
                    "name": "Children's Hospital of Philadelphia Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "John Maris", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jennifer.vest@stjude.org", 
                    "last_name": "Jennifer Vest", 
                    "phone": "901-595-2734"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105-2794"
                    }, 
                    "name": "St. Jude's Children's Research Hospital Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Giles Robinson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dione.froman@seattlechildrens.org", 
                    "last_name": "Dione Froman", 
                    "phone": "206-884-1214"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109-1023"
                    }, 
                    "name": "Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Dept Oncology"
                }, 
                "investigator": {
                    "last_name": "Julie Park", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Randwick", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2130"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3052"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "state": "Western Australia"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X8"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon Cedex", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75231"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augsburg", 
                        "country": "Germany", 
                        "zip": "86156"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50924"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "France", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LEE011 as a single agent", 
            "measure": "Incidence rate of dose limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "cycle 1 = 28 days (from the time of first dose)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747876"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Characterize the safety and tolerability of LEE011.", 
                "measure": "Number of patients with Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LEE011.", 
                "measure": "Changes in laboratory values", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 18 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LEE011.", 
                "measure": "Changes in electrocardiograms (ECGs)", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 18 months"
            }, 
            {
                "description": "Characterize the PK of LEE001 and any clinically significant metabolites that may be identified.", 
                "measure": "Plasma concentration time profiles", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Characterize the PK of LEE001 and any clinically significant metabolites that may be identified.", 
                "measure": "Pharmacokinetics (PK) parameters including but not limited to AUCtau, Cmax, Tmax, CL/F, accumulation ration (Racc) and T1/2, acc", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LEE011 by RECIST 1.1. In addition, for neuroblastoma, response by International neuroblastoma response criteria (INRC), for primary Central nervous system (CNS) tumors, response by Revised Assessment in Neuro-Oncology (RANO) Criteria.", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LEE011 by RECIST 1.1. In addition, for neuroblastoma, response by International neuroblastoma response criteria (INRC), for primary Central nervous system (CNS) tumors, response by Revised Assessment in Neuro-Oncology (RANO) Criteria.", 
                "measure": "Duration or response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LEE011. TTP per RECIST 1.1. In addition, for neuroblastoma, response by International neuroblastoma response criteria (INRC), for primary Central nervous system (CNS) tumors, response by Revised Assessment in Neuro-Oncology (RANO) Criteria.", 
                "measure": "Time to progression (TTP) per RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LEE011.", 
                "measure": "Number of patients with Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}